PubRank

Monica Hollstein

Author PubWeight™ 53.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002 12.39
2 TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010 4.92
3 p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007 3.86
4 p53 polymorphisms: cancer implications. Nat Rev Cancer 2009 3.33
5 Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle 2011 2.79
6 Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 2003 2.02
7 Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002 1.96
8 TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 2009 1.52
9 Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007 1.39
10 The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011 1.20
11 Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A 2004 1.16
12 Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006 1.15
13 How to become immortal: let MEFs count the ways. Aging (Albany NY) 2010 1.14
14 Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res 2012 1.05
15 MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 2006 1.04
16 DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004 0.99
17 Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem 2010 0.97
18 Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 2011 0.93
19 An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 2007 0.89
20 Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 2011 0.86
21 Upper urinary tract urothelial cancers: where it is A:T. Nat Rev Cancer 2012 0.85
22 Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc 2012 0.85
23 Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 2005 0.84
24 p53 designer genes for the modern mouse. Cell Cycle 2004 0.84
25 Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. Genet Eng (N Y) 2007 0.83
26 Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen 2012 0.82
27 Mouse models for generating P53 gene mutation spectra. Toxicol Lett 2002 0.79
28 A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem 2013 0.79
29 Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome. Mol Carcinog 2010 0.78
30 A VE-cadherin-PAR3-α-catenin complex regulates the Golgi localization and activity of cytosolic phospholipase A(2)α in endothelial cells. Mol Biol Cell 2012 0.76
31 Chek2ing out the p53 pathway: can Puma lead the way? Cell Cycle 2011 0.75
32 Corrigendum: Modelling mutational landscapes of human cancers in vitro. Sci Rep 2017 0.75